research and development

ChironWells focuses on lead identification and preclinical development of therapeutic drug candidates

of the morphinan class. ChironWells is technology leader in medicinal chemistry of morphinans and disposes of a

broad portfolio of composition of matter patents. The proprietary technology platform has led to a highly

competitive development portfolio of small molecules in commercially attractive therapeutic areas.

ChironWells’ primary therapeutic areas are:



Pain management: ChironWells develops safer opioid analgesics with a greatly improved side effect profile

as new medications for the treatment of moderate-to-severe acute and chronic pain.



Immunological diseases: New treatments are targeted to offer therapeutic improvement for patients

suffering of atopic dermatitis, psoriasis and rheumatoid arthritis.



Gastrointestinal disorders: ChironWells offers innovative pharmacotherapies for inflammatory bowel

diseases (IBD) including Morbus Crohn and ulcerative colitis, and bowel motility disorders including

postoperative ileus (POI) and opioid-induced bowel dysfunction (OBD).